|

Pegylated liposomal Doxorubicin (PLD) Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Doxil; Caelyx, Doxorubicin Hydrochloride Liposome Injection, duomeisu

Pipeline

Phase 3: 3

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Eli Lilly and Company1
  • AstraZeneca1

Indications

  • Cancer3
  • Peritoneal Neoplasms1
  • Fallopian Tube Neoplasms1
  • Ovarian Neoplasms1
  • Neoplasm Metastasis1

Other1 trial

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Phase 3

Birmingham, Alabama1 trial

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

University of Alabama at Birmingham

Phase 3

Fort Lauderdale, Florida1 trial

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.